Sorrento Therapeutics Inc (SRNE)

[dia76ca]

With increasing COVISTIX and ZTlido revenues and a blockbuster ABIVERTINIB partnership around the corner I look forward to all 3 areas of Sorrento's portfolio advancing this year. I do not know another small biotech that has as many shots on goal!
1. COVISTIX for affordable rapid accurate Covid testing followed by 2 minute COVISHIELD nasal drops or injections with COVI-MSC to prevent ARDS and treat LongHaul Covid are all very timely. And Mpro oral wide spectrum anti-viral with no drug/drug interaction limitations could be revolutionary!
2. SEMDEXA for sciatica, RTX for arthritic and cancer pain, SP-103 for acute back pain and SP-104 for fibromyalgia all hold great promise as non-opioid alternatives.
3. Sorrento's cancer portfolio is second to none. Abivertinib, CAR-Ts, DAR-Ts, ADCs, ADNABs and a second generation oncolytic virus are only the beginning. Many are first-in-class and best-in-class! And they treat literally dozens of specific cancer indications!

Q4 2021 revenues should be a nice surprise when announced in the next week or two. And Q1 2022 will be even better!